Search
Indapamide
go.drugbank.com/drugs/DB00808ApprovedInvestigational[A204134] When compared to [hydrochlorothiazide] (another commonly prescribed diuretic), indapamide has been shown to be superior at lowering systolic blood pressure, reducing left ventricular mass index … [A204155] Thiazide-like diuretics such as indapamide are a valuable tool for the treatment of hypertension and continue to grow in popularity, falling behind only ACE inhibitors in terms of prescription
Mixtures: COVERSYL PLUS Tablet 10mg/2.5mg, COVERSYL PLUS 10MG/2.5MG FILM-COATED TABLETBevifimod
go.drugbank.com/drugs/DB15301InvestigationalBevifimod is under investigation in clinical trial NCT01749787 (Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis).
Peanut oil
go.drugbank.com/drugs/DB13964ApprovedWithdrawn[A33169] Under the FDA, peanut oil is categorized as an approved inactive ingredient for its use in drug products. … [L2242] Under Health Canada, it is approved as an active ingredient in over-the-counter combination products.[L1113]
Dienogest
go.drugbank.com/drugs/DB09123ApprovedInvestigationalDienogest is commonly marketed as Visanne, Natazia and Qlaira. … It is a derivative of 19-nortestosterone and has antiandrogenic properties.
Dabrafenib
go.drugbank.com/drugs/DB08912ApprovedInvestigationalIt was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation.[L41955] It was also used for metastatic non-small cell lung cancer with the same mutation. … [L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955]
Futibatinib
go.drugbank.com/drugs/DB15149ApprovedInvestigationalFGFR was investigated in oncology as a therapeutic target, as FGFR genomic aberrations and dysregulated FGFR signalling pathways are observed in some cancers such as cholangiocarcinoma and urothelial malignancies … [A253193,A253198] As a novel inhibitor of FGFR, futibatinib was first approved by the FDA in September 2022 to treat different types of intrahepatic cholangiocarcinoma.
Etuvetidigene Autotemcel
go.drugbank.com/drugs/DB17593ApprovedInvestigational[L54693] WAS is a rare X-linked disorder caused by a mutation in the gene encoding the WAS protein, leading to a compromised immune system. … [A274878] The WAS protein is expressed on non-erythroid hematopoietic cells and regulates the function of actin filaments in the cytoskeleton.[A274878]
Synonyms: Autologous CD34+ cells transfected with lentiviral vector containing the human WAS cDNA (Telethon 003)Levopropoxyphene
go.drugbank.com/drugs/DB06793ApprovedWithdrawnIt was sold as an antitussive, but it was removed from the market in the 70s.[T133] Levopropoxyphene was developed by Lilly and FDA approved on March 21st, 1962. … This drug presented different dosages and it was administered as a capsule or suspension.
Pivopril
go.drugbank.com/drugs/DB19854ExperimentalThe usage of the INN stem '-pril' in the name indicates that Pivopril is a angiotensin-converting enzyme inhibitor. Pivopril has a monoisotopic molecular weight of 329.17 Da.
Utibapril
go.drugbank.com/drugs/DB20306ExperimentalThe usage of the INN stem '-pril' in the name indicates that Utibapril is a angiotensin-converting enzyme inhibitor. Utibapril has a monoisotopic molecular weight of 449.2 Da.